Menu
Menu
San Francisco, California – January 28, 2021 – OKAVA Pharmaceuticals, Inc., a clinical stage research and development company focused on diseases of aging in dogs and cats, today announced the publication of a proof-of-concept study in Frontiers in Veterinary Research, a leading peer-reviewed open access scientific journal. The publication details the clinical benefits of using advanced modified release drug delivery technology in dogs.
“OKAVA is the first company to utilize advanced drug delivery technologies for use in companion animals. This study demonstrates that meaningful clinical benefits of drug delivery, which have been available for decades in people, can also be applied to dogs,” said Michael Klotsman, PhD, MBA, the CEO of OKAVA. “It is our belief that by leveraging drug delivery technologies, we can unlock the clinical potential of existing human therapeutics to advance the well-being of pets.”
The laboratory-based study, performed in healthy Beagles, benchmarked the performance of OKV-1001 against immediate release (IR) CellCept®. Compared to CellCept®, approved for use in people by the FDA, the data generated shows that once-daily administration of OKV-1001 is more efficacious and better tolerated by dogs.
About OKV-1001
OKV-1001, a patented modified-release mycophenolate formulation, is the first-ever product candidate to leverage advanced drug delivery technologies to meet the unique needs of dogs. OKV-1001 is a MUMS-designated product that is under development for immune-mediated inflammatory conditions. In people, mycophenolate is an FDA-approved medicine used across a host of immune-mediated inflammatory diseases including atopic dermatitis, immune-mediated hemolytic anemia, and lupus.
OKAVA’s proprietary OKV-1001 formulation is a once-daily oral product designed to unlock the therapeutic potential of mycophenolate by improving the ease-of-use, safety, and efficacy of this drug.
About OKAVA Pharmaceuticals, Inc.
OKAVA is a clinical-stage research and development company that develops new treatment options for dogs and cats suffering from chronic diseases of aging. OKAVA is building a portfolio of products to transform and humanize standards of care in veterinary medicine. By harnessing human technologies for the treatment of common diseases in household pets, the company has the potential of increasing the lifespans of dogs and cats by an average of 1 to 3 years. OKAVA is a private company headquartered in San Francisco, California. For more information, see OKAVApharma.com.
About OKAVA Pharmaceuticals, Inc.
OKAVA is a clinical-stage research and development company that develops new treatment options for dogs and cats suffering from chronic diseases of aging. OKAVA is building a portfolio of products to transform and humanize standards of care in veterinary medicine. By harnessing human technologies for the treatment of common diseases in household pets, the company has the potential of increasing the lifespans of dogs and cats by an average of 1 to 3 years. OKAVA is a private company headquartered in San Francisco, California. For more information, see OKAVApharma.com.
For More Information:
Michael Klotsman, PhD, MBA Chief Executive Officer at OKAVA
Phone: 415.818.1808
Copyright © 2024 Okava Pharmaceuticals. All rights reserved.